KKR's Gamma Biosciences platform has committed $54.1m in financing to a new subsidiary of Univercells, whose existing investors include Takeda.
Univercells, a Belgium-based biologics development technology provider that counts pharmaceutical firm Takeda as an investor, agreed up to €50m ($54.1m) in financing from investment firm KKR’s Gamma Biosciences vehicle yesterday.
Founded in 2013, Univercells is developing technology that will enable businesses to create biotherapeutics and vaccines at more affordable prices. The money will go to a newly formed Univercells subsidiary tasked with commercialising its manufacturing technologies.
The unit is prioritising the company’s NevoLine vaccine biomanufacturing system and a range of…
